Nguyen T. V. A. auteur aut IRD Anthony R. M. auteur aut IRD Cao T. T. H. auteur aut IRD Banuls Anne-Laure auteur aut IRD Nguyen V. A. T. auteur aut IRD Vu D. H. auteur aut IRD Nguyen N. V. auteur aut IRD Alffenaar J. W. C. auteur aut IRD text journalArticle eng text/pdf born digital access Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence. This review provides information on the mechanisms of action, resistance emergence, and drug susceptibility testing (DST) for delamanid. Delamanid resistance has already been reported in both in vitro experiments and clinical settings. Although mutations conferring delamanid resistance have been identified in fbiA, fbiB, fbiC, ddn, and fgd1 genes of Mycobacterium tuberculosis, knowledge about the molecular resistance mechanisms is limited, and there remains no standardized DST method. The rapid acquisition of delamanid resistance emphasizes the need for optimal use of new drugs, the need for drug resistance surveillance, and a comprehensive understanding of drug resistance mechanisms. Further studies are necessary to investigate genetic and phenotypic changes that determine clinically relevant delamanid resistance to help develop a rapid delamanid DST. specialized delamanid drug resistance tuberculosis drug susceptibility testing pharmacokinetics pharmacodynamics 050 084 71 12 3252-3259 2020 1058-4838 https://www.documentation.ird.fr/hor/fdi:010080935 10.1093/cid/ciaa755 1058-4838 [F B010080935] https://www.documentation.ird.fr/hor/fdi:010080935 https://www.documentation.ird.fr/intranet/publi/2021/03/010080935.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2021-04-01 2025-02-24 fdi:010080935 fre